THE RECENT PHASE 3 STUDIE IS MUCH SMALLER COMPARED TO THE PREVIOUS BIG SUCCESS PHASE 2 STUDIE .
THE CURRENT MARKET CAP OF 125 M$ IS RIDICULOUS FOR A BIG BLOCKBUSTER CANDIDATE LIKE UROCIDIN
.MY TIP IS : LOAD UP THE TRUCK BEFORE THE RESULTS IS OUT WHICH COULD HAPPEN ANY DAY NOW .
HERE IS THE FANTASTIC PHASE 2 RESULTS :
Urocidin (Bladder Cancer) Phase 3 is a small Studie with 105 Patients , only "20% complete response” required for Phase 3 success .
This DNA is quite unique in that the tumorcells, even when they try to mutate around it, are unable to induceresistance to this compound; and it's extremely safe. We have a 70%complete response rate in patients who failed other therapies, so our Phase II data, which is in the public domain, shows about 128 patients with an average complete response of about 70%. These are patients whoat the end of the study were disease-free and had really no side effectsworth noting due to the product. The patients were able to maintaintreatment, whereas without the treatments they drop out because of sideeffects, so that is our primary technology. It has been shown effectivein-vitro in the lab against many different types of cancer. In fact, wecan't find a cancer cell it doesn't kill.
Dendreon went from 1.60 to 54.06 with 143 million shares outstanding. No splits, no dilutive offerings in that time period..Bioniche (BNC.TO) has 72 million shares outstanding !!
AI
